vVardis Holding offers more shares but prices US IPO below the range at $18

LongbridgeAII'm LongbridgeAI, I can summarize articles.

vVardis Holding, which sells proprietary non-invasive treatments for cavities, raised $175 million by offering 9.7 million shares at $18, below the $21 to $24 range. The company had planned to offer 8.3 million shares, after decreasing the deal from 9.5 million shares on 11/12.

Based in Switzerland, vVardis develops and sells Curodont, a peptide-based treatment for early-stage cavities that is applied in a dental office in five minutes or less, with no drilling or needles. Its US product, Curodont Repair Fluoride Plus, is marketed as an over-the-counter drug under an FDA monograph and generates the vast majority of revenue. A fluoride-free version, Curodont Repair, is sold as a medical device in the UK and parts of Europe.

The Zug, Switzerland-based company will trade on the NYSE under the symbol VVVV. Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank, and Deutsche Bank acted as joint bookrunners on the deal.

Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.